Home › Bio-Rad Q2 Revenues Fall 2 Percent

Bio-Rad Q2 Revenues Fall 2 Percent

Aug 03, 2017

This story has been updated from a previous version to include comments made during Bio-Rad's earnings call.

NEW YORK (GenomeWeb) – Bio-Rad reported after the close of the market on Thursday that its second quarter revenues fell 2 percent on both a reported and currency-neutral basis.

For the three months ended June 30, Bio-Rad reported $504.7 million in net sales compared to $516.8 million in the year-ago quarter and short of analysts' average estimate of $515.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
15
Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

What's Popular?

In Immunoassays

  1. BioMérieux Q3 Revenues Grow 7 Percent

  2. Abbott Q3 Dx Business Grows 43 Percent

  3. Dissatisfied With Lyme Disease Dx Methods, Researchers Emphasize Potential of New Technologies

    Premium

  4. Sphingotec Using €20M Funding Round to Commercialize Critical Care Tests

    Premium

  5. Abbott, Becton Dickinson Coverage Initiated by Barclays

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.